These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30465818)

  • 1. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tackling the challenges of nanomedicines: are we ready?
    Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
    Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosimilars: A Scientific or A Regulatory Debate?
    Demetzos C
    AAPS J; 2024 Jul; 26(4):74. PubMed ID: 38955936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractal geometry as a new approach for proving nanosimilarity: a reflection note.
    Demetzos C; Pippa N
    Int J Pharm; 2015 Apr; 483(1-2):1-5. PubMed ID: 25659328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to select a nanosimilar.
    Astier A; Barton Pai A; Bissig M; Crommelin DJA; Flühmann B; Hecq JD; Knoeff J; Lipp HP; Morell-Baladrón A; Mühlebach S
    Ann N Y Acad Sci; 2017 Nov; 1407(1):50-62. PubMed ID: 28715605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
    Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
    Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
    Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
    AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanosize drug delivery system.
    Mukherjee B
    Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevant Physicochemical Descriptors of "Soft Nanomedicines" to Bypass Biological Barriers.
    Nino-Pariente A; Nebot VJ; Vicent MJ
    Curr Pharm Des; 2016; 22(9):1274-91. PubMed ID: 26675217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated nanomedicines: recent progress and remaining concerns.
    Vllasaliu D; Fowler R; Stolnik S
    Expert Opin Drug Deliv; 2014 Jan; 11(1):139-54. PubMed ID: 24295065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines - Tiny particles and big challenges.
    Marques MRC; Choo Q; Ashtikar M; Rocha TC; Bremer-Hoffmann S; Wacker MG
    Adv Drug Deliv Rev; 2019; 151-152():23-43. PubMed ID: 31226397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.